A plain language summary of the INTRIGUE study comparing ripretinib with sunitinib in people with advanced gastrointestinal stromal tumour after treatment with imatinib
This Plain Language Summary of Publication article from Future Oncology a phase 3 study called INTRIGUE. The aim of the study was to understand whether treatment with a drug called ripretinib (brand name QINLOCK®) was superior to treatment with sunitinib (brand name SUTENT®) in participants with advanced gastrointestinal stromal tumor (also known as GIST) who cannot tolerate or whose disease worsened after first-line treatment with imatinib (brand name GLEEVEC®).
Please visit Future Medicine using the link to read the full article
The original article on which this summary is based is called ‘Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial’. It was published in the Journal of Clinical Oncology.
Please visit ASCO Publications using the link to read the full article.